Working… Menu

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03421431
Recruitment Status : Completed
First Posted : February 5, 2018
Last Update Posted : October 10, 2019
ICON Clinical Research
Triangle Biostatistics
Information provided by (Responsible Party):
Enanta Pharmaceuticals

Brief Summary:
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis

Condition or disease Intervention/treatment Phase
Non-Alcoholic Steatohepatitis Drug: EDP-305 Dose 1 Drug: EDP-305 Dose 2 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 134 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Actual Study Start Date : April 25, 2018
Actual Primary Completion Date : June 14, 2019
Actual Study Completion Date : July 10, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EDP-305 Dose 1
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 Dose 1
Two tablets daily for 12 weeks

Experimental: EDP-305 Dose 2
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 Dose 2
Two tablets daily for 12 weeks

Placebo Comparator: Placebo
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: Placebo
Two tablets daily for 12 weeks

Primary Outcome Measures :
  1. Change from baseline in ALT levels at Week 12 [ Time Frame: Measurement at Week 12 ]
  2. Safety as measured by frequency of adverse events (AEs), serious AEs, and AEs leading to discontinuation through Week 12 [ Time Frame: Up to 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • An informed consent document must be signed and dated by the subject
  • Male and female subjects of any ethnic origin between the ages of 18 and 75 years, inclusive
  • Male or female with presence of NASH by:

    • Histologic evidence on a historical liver biopsy within 24 months of Screening consistent with NASH with fibrosis (no cirrhosis), and elevated ALT at Screening AND Screening MRI PDFF with >8 % steatosis OR
    • Phenotypic diagnosis of NASH based on elevated ALT and diagnosis of T2DM or pre-diabetes AND Screening MRI PDFF with >8 % steatosis
  • Body mass index (BMI) >25 kg/m2; for Asian-Americans, BMI >23 kg/m2
  • Female subjects of childbearing potential must agree to use two effective methods of contraception from the date of Screening until 90 days after the last dose of EDP-305.
  • Subject must be willing and able to adhere to the assessments, visit schedules, prohibitions and restrictions, as described in this protocol

Exclusion Criteria:

  • Laboratory Screening Results:

    • Total bilirubin > ULN (normal range 0.2-1.2 mg/dL)
    • Total white blood cells (WBC) <3,000 cells/mm3
    • Absolute neutrophil count (ANC) <1,500 cells/mm3
    • Platelet count <140,000/mm3
    • Prothrombin time (international normalized ratio, INR) > 1.2
    • Creatine kinase above the upper limit of normal (ULN) except when in relation with intense exercise
    • Serum creatinine >2 mg/dL or creatinine clearance <60 ml/min (based on Cockroft Gault method)
  • Known history of alpha-1-antitrypsin deficiency
  • Use of an experimental treatment for NASH within the past 6 months
  • Use of immunosuppressant (eg, corticosteroids) for more than 2 weeks in duration within 1 year prior to Screening and during the course of the study
  • Use of experimental or unapproved drugs within a year of Screening
  • Any other condition(s) (including cardiovascular diseases) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Principal Investigator (PI)
  • Pregnant or nursing females
  • Recipients of liver or other organ transplantation or anticipated need for orthotropic organ transplantation in one year as determined by a Model for End-Stage Liver Disease (MELD) Score ≥ 15
  • Clinical suspicion of advanced liver disease or cirrhosis
  • Coexisting liver or biliary diseases, such as primary sclerosing cholangitis (PSC), choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver disease, acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), cirrhosis
  • Suspicion of cancer (eg, liver cancer) with the exception of basal cell carcinoma that has been resected
  • Cirrhosis with or without complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2xULN
  • Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178 μmol/L)
  • Prior variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class A, B, and C, esophageal varices, or refractory ascites within the previous 6 months of Screening (defined as date informed consent signed)
  • Any condition possibly affecting drug absorption (eg, gastrectomy <3 years prior to Screening)
  • Subject has received an investigational agent or vaccine within 30 days, or a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to the planned intake of study drug. NOTE: Flu vaccine will be allowed upon Medical Monitor's approval
  • Use of a new statin regimen from Screening and throughout study duration. NOTE: Subjects on a stable dose of statins for at least three months prior to Screening are allowed. No dose modification during the study will be allowed.
  • Current use of fibrates. Note: Subjects who discontinued fibrates for at least 3 months before Screening can participate
  • Clinically significant history of drug sensitivity or allergy, as determined by the PI
  • Uncontrolled diabetes mellitus (ie, HbA1c ≥9% or higher) 60 days prior to Day 1
  • Subjects with contraindications to MRI imaging, or not being able to have the MRI performed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03421431

Show Show 82 study locations
Sponsors and Collaborators
Enanta Pharmaceuticals
ICON Clinical Research
Triangle Biostatistics
Layout table for investigator information
Study Director: Nathalie Adda, MD Enanta Pharmaceuticals Inc.
Layout table for additonal information
Responsible Party: Enanta Pharmaceuticals Identifier: NCT03421431    
Other Study ID Numbers: EDP 305-101
First Posted: February 5, 2018    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Enanta Pharmaceuticals:
Non-Alcoholic Steatohepatitis (NASH)
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases